The federal executive order on cannabis rescheduling does NOT make recreational marijuana legal—it eases research restrictions and tax burdens, but full legalization still requires an act of Congress. OpenPR reports that the clinical trial pipeline for cannabis use disorder (CUD) treatments is gaining momentum, with pharmaceutical R&D intensifying focus on targeted therapies. Aelis Farma is advancing AEF0117, a selective CB1 modulator, through Phase II trials.